The DOI matches its Crossref record.
Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study
Abstract
OBJECTIVE: To evaluate the efficacy and safety of olanzapine, divalproex, and placebo in a randomized, double-blind trial in mild to moderate mania (DSM-IV-TR criteria). METHOD: The study was conducted from October 2004 to December 2006. A total of 521 patients from private practices, hospitals, and university clinics were randomly assigned to olanzapine (5-20 mg/day), divalproex (500-2500 mg/day), or placebo for 3 weeks; those completing continued with a 9-week double-blind extension. Efficacy (mean change in Young Mania Rating Scale [YMRS] total score was the primary outcome) and safety were assessed. RESULTS: After 3 weeks of treatment, olanzapine-treated (N = 215) and placebo-treated (N = 105) patients significantly differed in YMRS baseline-to-endpoint total score change (p = .034; least squares [LS] mean: -9.4 and -7.4, respectively). Such changes were not significantly different between olanzapine vs. divalproex (N = 201) or divalproex vs. placebo. After 12 weeks of treatment, olanzapine- and divalproex-treated patients significantly differed in YMRS baseline-to-endpoint changes (p = .004; LS mean: -13.3 and -10.7, respectively). Of observed cases, 35.4% (35/99; 3 weeks) to 57.1% (28/49; 12 weeks) had valproate plasma concentrations lower than the recommended valproate therapeutic range, but these patients' YMRS scores were lower than those of patients with valproate concentrations above/within range. Compared with divalproex, after 12 weeks, olanzapine-treated patients had significant increases in weight (p < .001) and in glucose (p < .001), triglyceride (p = .003), cholesterol (p = .024), uric acid (p = .027), and prolactin (p < .001) levels. Divalproex-treated patients had significant decreases in leukocytes (p = .044) and platelets (p < .001) compared with olanzapine after 12 weeks of treatment. The incidence of potentially clinically significant weight gain (>/= 7% from baseline) was higher with olanzapine than with divalproex (3-week: p = .064, 6.4% vs. 2.7%; 12-week: p = .002, 18.8% vs. 8.5%; respectively). CONCLUSION: Olanzapine was significantly more efficacious than placebo but not divalproex at 3 weeks and significantly more efficacious than divalproex at 12 weeks. Olanzapine-treated patients had significantly greater increases in weight and in glucose, cholesterol, triglyceride, uric acid, and prolactin levels than divalproex-treated patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00094549.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies of olanzapine (level 2 negative) 173 or risperidone (level 3 negative)174 plus carbamazepine have been negative, although this is probably due to enzyme‐inducing effects of carbamazepine.”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationEfficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
Yildiz, A., Vieta, E., Leucht, S., & Baldessarini, R. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.192 · Cited by 252
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“Finally, another RCT compared the efficacy of olanzapine versus valproate or placebo in manic/mixed patients (Tohen et al. 2008).”
ResultSelf-citation
Metadata
- Authors
- Tohen, M., Vieta, E., Goodwin, G. M., Sun, B., Amsterdam, J. D., Banov, M., Shekhar, A., Aaronson, S. T., Bardenstein, L., Grecu-Gabos, I., Tochilov, V., Prelipceanu, D., Oliff, H. S., Kryzhanovskaya, L., & Bowden, C.
- Affiliations
- Harvard University (US)
- University of Oxford (GB)
- Eli Lilly (United States) (US)
- University of Pennsylvania (US)
- Northwest Behavioral Medicine (US)
- Indiana University – Purdue University Indianapolis (US)
- Sheppard Pratt Health System (US)
- North-Western State Medical University named after I.I. Mechnikov (RU)
- Scientific Consulting Group (US)
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-11-30
- Volume
- 69
- Issue
- 11
- Pages
- 1776-1789
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2059471127
- Cited by
- 87
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 7 · 2014: 2 · 2013: 2 · 2012: 14
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- olanzapine, divalproex, valproic acid, mania, bipolar disorder, antipsychotic drugs, Young Mania Rating Scale, drug safety, weight gain, prolactin, leukopenia, hypertriglyceridemia, treatment efficacy comparison, adverse effects, mood stabilizers
- MeSH terms
- Olanzapine, Adolescent, Adult, Aged, Benzodiazepines, Bipolar Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Prolactin, Antipsychotic Agents, Valproic Acid, Weight Gain, Least-Squares Analysis, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study. https://app.cochat.ai/papers/10.4088/jcp.v69n1113
- The paper
- Tohen, M., Vieta, E., Goodwin, G. M., Sun, B., Amsterdam, J. D., Banov, M., Shekhar, A., Aaronson, S. T., Bardenstein, L., Grecu-Gabos, I., Tochilov, V., Prelipceanu, D., Oliff, H. S., Kryzhanovskaya, L., & Bowden, C. (2008). Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n1113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.